Dermorphin vs Diclofenac Topical
A side-by-side research comparison of Dermorphin and Diclofenac Topical across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dermorphin | Diclofenac Topical |
|---|---|---|
| Full name | Dermorphin (Opioid Heptapeptide) | Diclofenac Sodium Topical Gel (Voltaren) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Research compound | FDA Approved (OTC) |
| Mechanism | Binds mu-opioid receptors with very high affinity and selectivity, producing potent analgesia. Its unusual D-alanine residue makes it resistant to breakdown, contributing to a much stronger effect than morphine on a per-weight basis. | Inhibits cyclooxygenase-1 and -2 (COX-1/2) locally in tissue, reducing prostaglandin E2 synthesis at the inflammation site. Topical delivery achieves therapeutic tissue concentrations with plasma levels <5% of oral dosing. |
| Molecular weight | 803.9 Da | 318.13 Da (sodium salt) |
| Half-life | Short (peptide) | ~1-2 hours (plasma); tissue penetration lasts 12+ hours |
| Bioavailability | Injection (research) | ~6% systemic (topical); local tissue levels therapeutic |
| Typical dose | Not established for human use | 4g gel (1% or 2%) per joint |
| Frequency | Research only | 3-4x daily |
| Route | Injection (research) | Topical gel |
Dermorphin reported benefits
- Potent analgesia (research context)
- High mu-opioid receptor selectivity (research interest)
Diclofenac Topical reported benefits
- Localized pain relief
- Minimal systemic side effects
- Joint and tendon inflammation
- Post-workout recovery
- No GI ulcer risk
- OTC availability
Related comparisons
Research and educational reference only. Not medical advice.